Search research articles
Contact Us
Filters
Showing results (11-20 of 64) with videos related to
Page
of 7
Sort By:
The Journal of Reproductive Medicine
|
July 3, 2002
Twenty-five years' clinical experience with placental site trophoblastic tumors
Andreas J Papadopoulos, Marianne Foskett, Michael J Seckl, et al.
Cancer Treatment Reviews
|
September 26, 2021
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas
Benoit You, Gilles Freyer, Antonio Gonzalez-Martin, et al.
Inflammation
|
April 28, 2021
The Emerging Role of Interleukin 1β (IL-1β) in Cancer Cachexia
Barry J Laird, Donald McMillan, Richard J E Skipworth, et al.
The Journal of Experimental Medicine
|
May 21, 2008
"Re-educating" tumor-associated macrophages by targeting NF-kappaB
Thorsten Hagemann, Toby Lawrence, Iain McNeish, et al.
International Journal of Molecular Medicine
|
April 6, 2006
Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo
Pilar Martín-Duque, Miguel Quintanilla, Iain McNeish, et al.
Future Oncology (London, England)
|
November 29, 2024
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success
Ashton Hunt, Daria Ditri, Ankit Chadha, et al.
Ebiomedicine
|
February 21, 2023
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10
Olivier Colomban, Elizabeth M Swisher, Rebecca Kristeleit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2006
Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment
Nirupa Murugaesu, Peter Schmid, Gairin Dancey, et al.
Cell Reports
|
October 20, 2023
Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma
Yuewei Xu, Sarah Spear, Yurui Ma, et al.
Cancer Research
|
March 16, 2011
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer
Nelofer Syed, Helen M Coley, Jalid Sehouli, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 64) with videos related to
Sort By:
Page
of 7
The Journal of Reproductive Medicine
|
July 3, 2002
Twenty-five years' clinical experience with placental site trophoblastic tumors
Andreas J Papadopoulos, Marianne Foskett, Michael J Seckl, et al.
Cancer Treatment Reviews
|
September 26, 2021
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas
Benoit You, Gilles Freyer, Antonio Gonzalez-Martin, et al.
Inflammation
|
April 28, 2021
The Emerging Role of Interleukin 1β (IL-1β) in Cancer Cachexia
Barry J Laird, Donald McMillan, Richard J E Skipworth, et al.
The Journal of Experimental Medicine
|
May 21, 2008
"Re-educating" tumor-associated macrophages by targeting NF-kappaB
Thorsten Hagemann, Toby Lawrence, Iain McNeish, et al.
International Journal of Molecular Medicine
|
April 6, 2006
Caspase-1 as a radio- and chemo-sensitiser in vitro and in vivo
Pilar Martín-Duque, Miguel Quintanilla, Iain McNeish, et al.
Future Oncology (London, England)
|
November 29, 2024
Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success
Ashton Hunt, Daria Ditri, Ankit Chadha, et al.
Ebiomedicine
|
February 21, 2023
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10
Olivier Colomban, Elizabeth M Swisher, Rebecca Kristeleit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2006
Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment
Nirupa Murugaesu, Peter Schmid, Gairin Dancey, et al.
Cell Reports
|
October 20, 2023
Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma
Yuewei Xu, Sarah Spear, Yurui Ma, et al.
Cancer Research
|
March 16, 2011
Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer
Nelofer Syed, Helen M Coley, Jalid Sehouli, et al.
Page
of 7